# Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

> **NCT05804032** · PHASE3 · COMPLETED · sponsor: **University of Heidelberg Medical Center** · enrollment: 514 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** Isatuximab
- **DRUG:** Lenalidomide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05804032
- **Lead sponsor:** University of Heidelberg Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-14
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05804032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05804032, "Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05804032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*